Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

Rosenstock, Julio; Aronson, Ronnie; Grunberger, George; Hanefeld, Markolf; Piatti, PierMarco; Serusclat, Pierre; Cheng, Xi; Zhou, Tianyue; Niemoeller, Elisabeth; Souhami, Elisabeth; Davies, Melanie; behalf of the LixiLan-O Trial Investigators, on

doi:10.2337/dc16-0917

Public

Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial

Shared by NobleBlocks on Aug 15, 2016 • 12:00 AM UTC

Authors:

Julio Rosenstock

Ronnie Aronson

George Grunberger

Abstract

OBJECTIVE To evaluate efficacy and safety of LixiLan (iGlarLixi), a novel titratable fixed-ratio combination of insulin glargine (iGlar) and lixisenatide (Lixi), compared with both components, iGlar and Lixi, given separately in type 2 diabetes inadequately controlled on metformin with or without a ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!